The following is a CancerGRACE article by Dr. Howard (Jack) West. Dr. West is a lung cancer specialist at Swedish Medical Center in Seattle, WA. Dr. West's nonprofit organization, CancerGRACE, provides expert-mediated information on current and emerging cancer management options in order to empower patients, caregivers, and health professionals to become direct partners in cancer care.
Upping the Ante in the Face of Progression
Today I’m going to veer into the realm of style in cancer management rather than focusing on hard evidence. Sadly, it’s not a rare event to have cancer progress early despite a perfectly good initial therapy. I just saw a patient in my clinic who illustrates what I consider to be a very reasonable treatment idea that doesn’t find its way into the textbook approaches for managing somewhat resistant cancers, but it’s worth discussing the concept of upping the ante with subsequent treatment.
To back up, the textbook answer to what to do in the face of a cancer that is progressing through first line treatment is to move on to second line treatment, though we know that our second line treatments tend to be less effective than earlier ones, and that early progression through good first line therapy represents a high probability that this is a pretty resistant cancer.
The particular patient I saw had been referred by a very good community oncologist for a second opinion after she had just had a scan that demonstrated a mixed response to first line carboplatin/Taxol (paclitaxel) for advanced squamous cell NSCLC, with more progression than response. She’s relatively young, with a very good performance status, and despite the findings of progression, is still looking and feeling very well.While the standard approach for second line treatment for her squamous NSCLC would be either Taxotere (docetaxel) or Tarceva (erlotinib), it’s hard to be extremely optimistic about either of these for her. Taxotere, a cousin of Taxol, could be better than the carbo/Taxol doublet, but I think that’s pretty unlikely. Tarceva certainly can prolong survival in squamous cell NSCLC, but it doesn’t tend to be a blockbuster in this setting.
------- Finish reading the article HERE -----